Momenta Pharmaceuticals, Inc. is a biotechnology company specializing in the detailed structural analysis and design of complex sugars (polysaccharides) for the development of improved versions of existing drugs, the development of novel drugs, and the discovery of new biological processes. We are also utilizing our ability to sequence, or analyze the molecular structure of, sugars to create technology-enabled generic versions of complex sugar-based products. Our most advanced product candidate, M-Enoxaparin, is designed to be a technology-enabled generic version of Lovenox®, a widely prescribed low molecular weight heparin, or LMWH. Our novel product candidates include M118, a LMWH for the treatment of acute coronary syndromes that has been designed to possess specific biological attributes as well as a technology that has been designed to use specific sugar sequences to improve the non-invasive delivery of drugs such as therapeutic proteins.

Through detailed analysis of the molecular structure of complex sugars, our technology provides a more complete understanding of the roles that sugars play in cellular function, disease, and drug action. While it has been recognized that sugars play fundamental roles in the regulation of biological activity, the technical and analytic challenges associated with sequencing complex sugars have hindered a comprehensive understanding of their role in disease biology as well as in drug action. We believe understanding the structure, specific function, and manner in which complex sugars affect critical biological processes and existing therapeutics will provide significant opportunities for drug discovery and development. Momenta was founded in 2001 based on technology developed at the Massachusetts Institute of Technology (MIT).

Applying Technology to Products

Momenta is applying its technology and its understanding of complex sugars to product development in three primary ways:

• Characterizing Products to Enable Generics: Our most advanced product candidates are designed to be technology-enabled generic versions of complex drug products. Our first product candidates are generic versions of LMWHs, such as the drug Lovenox®, which are used to prevent and treat deep vein thrombosis and treat acute coronary syndromes.
  
• Improved Therapeutics: Momenta has the ability to rationally design heparins or other products containing sugars in order to address specific unmet needs, as in the case of M118, our leading novel development candidate. We believe that our ability to identify sugar structures, correlate them to biological activity, and engineer these sugar structures will lead to improved drugs with enhanced clinical activity, reduced toxicity, and optimal half-life. We believe we can also apply our technology using specific sugar sequences to non-invasively deliver drugs, such as therapeutic proteins, which have only been available by injectable administration to date.
  
• Discover Novel Drugs: We intend to apply our understanding of the role sugars play in basic biology and in disease onset, progression, and treatment to develop novel sugar-based, small molecule and antibody drugs addressing critical unmet medical needs in a range of diseases including cancer, cardiovascular disease, Alzheimer’s Disease, inflammatory disease, and viral infection.
  

Momenta seeks to capitalize on near-term revenue opportunities which can be used to foster long-term growth and to partially fund our discovery and development programs. We simultaneously plan to advance improved versions of existing products as well as novel discovery candidates, based on our understanding of sugars’ role in disease biology and drug action, through clinical development to commercialization.